Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with <i>EGFR</i> G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review

Epidermal growth factor receptor (<i>EGFR</i>) tyrosine kinase inhibitors (TKIs) are effective in non-small-cell lung cancer (NSCLC) with sensitizing mutations. However, patients with uncommon <i>EGFR</i> mutations show variable responses, and resistance often develops. The C...

書誌詳細
出版年:	Current Oncology
主要な著者:	Wenting Lu, Jiayi Sun, Yawan Jing, Jing Xu, Chengming Huang, Yi Deng, Panwen Tian, Yalun Li
フォーマット:	論文
言語:	英語
出版事項:	MDPI AG 2025-03-01
主題:	NSCLC <i>EGFR</i> mutation <i>EGFR</i>-TKI osimertinib gefitinib bevacizumab
オンライン･アクセス:	https://www.mdpi.com/1718-7729/32/4/201

類似資料

Complete response in a lung adenocarcinoma with pleural metastases initially treated with gefitinib and switched to osimertinib after cerebral oligo-progression with unknown T790M mutation: a case report and review of literature
著者:: Mariem Hachlaf, 等
出版事項: (2024-08-01)

Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis
著者:: Taisuke Ito, 等
出版事項: (2024-01-01)

Pharmacokinetics comparison of aumolertinib, osimertinib, gefitinib and their major metabolites in mouse model and NSCLC patients
著者:: Ran Ren, 等
出版事項: (2024-12-01)

Osimertinib-Induced Hepatitis Following Immunotherapy in a Patient with Lung Adenocarcinoma Harboring De Novo EGFR Exon 19 Deletion and T790M Mutations: A Case Report
著者:: Bradley Steiner, 等
出版事項: (2025-06-01)

Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
著者:: Yingqi Xu, 等
出版事項: (2025-12-01)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
著者:: Hanping Wang, 等
出版事項: (2020-03-01)

Liquid Biopsy in <i>EGFR</i>-Mutated Advanced NSCLC from T790M to <i>MET</i> Amplification: Clinical Implications and Possibilities in the Resistance Setting
著者:: Luigi Della Gravara, 等
出版事項: (2023-04-01)

Drug-induced subacute cutaneous lupus erythematosus involving osimertinib
著者:: Christian L. Bailey-Burke, AB, 等
出版事項: (2024-11-01)

Airway stenosis secondary to mediastinal lymph node metastasis of lung adenocarcinoma treated with AERO stent and osimertinib: A case report
著者:: Yuki Takigawa, 等
出版事項: (2024-05-01)

Uncommon <i>EGFR</i> Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
著者:: Ilaria Attili, 等
出版事項: (2022-01-01)

Safety and efficacy of the combination of selpercatinib with osimertinib in NSCLC: a case report and review of the literature
著者:: Blerina Resuli, 等
出版事項: (2025-05-01)

First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report
著者:: Yugo Matsumura, 等
出版事項: (2025-07-01)

Prolonged Response to Osimertinib in EGFR-Mutated Metastatic Urothelial Carcinoma, a Case Report
著者:: Sareen T. Ali, 等
出版事項: (2024-07-01)

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
著者:: Jae Cheol Lee, 等
出版事項: (2021-05-01)

Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
著者:: Y. Uehara, 等
出版事項: (2024-09-01)

Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review)
著者:: O.M. Smorodska, 等
出版事項: (2021-06-01)

Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
著者:: Takahiro Uchida, 等
出版事項: (2019-04-01)

Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India
著者:: Atul Tiwari, 等

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
著者:: Yosuke Miyashita, 等
出版事項: (2021-02-01)

Case Report: Osimertinib-induced acute interstitial lung disease
著者:: Zhiwu Lin, 等
出版事項: (2025-06-01)

Dynamic Evaluation of Circulating miRNA Profile in <i>EGFR</i>-Mutated NSCLC Patients Treated with EGFR-TKIs
著者:: Alessandro Leonetti, 等
出版事項: (2021-06-01)

Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for <i>EGFR</i> Mutation-Positive Patients Treated with First-Line Osimertinib
著者:: Amanda Jane Williams Gibson, 等
出版事項: (2024-04-01)

CircSPINT2 confers sensitivity to osimertinib via hsa-miR-1296-3p/RBP1 axis and inhibits NSCLC progression
著者:: Nalini Devi Verusingam, 等
出版事項: (2025-09-01)

SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma
著者:: Patricia L. Theard, 等
出版事項: (2024-03-01)

Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR‐mutated NSCLC
著者:: Yusuke Hamakawa, 等
出版事項: (2023-09-01)

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
著者:: Tia Cheunkarndee, BA, 等
出版事項: (2024-06-01)

HDAC5, an early osimertinib-responsive gene, is a novel therapeutic target for the drug resistance in EGFR-mutant lung adenocarcinoma cells
著者:: Hanbing Lyu, 等
出版事項: (2025-06-01)

Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation
著者:: Shanliang Hu, 等
出版事項: (2022-08-01)

Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated With Osimertinib: A Case Report
著者:: Sunny Y. Lai, MD, 等
出版事項: (2024-04-01)

Clinical study of aumolertinib versus osimertinib in the treatment of EGFR-mutated advanced non-small cell lung cancer
著者:: Sheng-Xi Yang, 等
出版事項: (2025-10-01)

Osimertinib‐induced BRAF mutation in a single metastatic lesion among multiple pulmonary lesions in a case of lung cancer with EGFR exon 19 deletion
著者:: Hiroyuki Miura, 等
出版事項: (2024-08-01)

Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study
著者:: Jixian Li, 等
出版事項: (2025-07-01)

Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?
著者:: Zhang SS, 等
出版事項: (2022-10-01)

Efficacy of befotertinib in non-small cell lung cancer harboring uncommon compound EGFR mutations G719X and S768I: a case report
著者:: Zhedong Zhang, 等
出版事項: (2024-04-01)

OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs
著者:: Richard E. Kast, 等
出版事項: (2021-05-01)

Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M‐positive non‐small cell lung cancer
著者:: Hye Sook Kim, 等
出版事項: (2023-06-01)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
著者:: Jiao‐Li Wang, 等
出版事項: (2022-11-01)

The Root Extract of <i>Peucedanum praeruptorum</i> Dunn Exerts Anticancer Effects in Human Non-Small-Cell Lung Cancer Cells with Different <i>EGFR</i> Mutation Statuses by Suppressing MET Activity
著者:: Hyun-Ji Park, 等
出版事項: (2022-04-01)

Advanced lung adenocarcinoma harboring uncommon EGFR 19 Del and T790M/trans-C797S mutations after resistance: a case report and literature review
著者:: Yuting Xiao, 等
出版事項: (2025-04-01)

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
著者:: Hsu-Yuan Chen, 等
出版事項: (2024-10-01)